Seung‐Oe Lim
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
80
Citations
1,354
Est. group size
~6
Recurring co-author estimate
Active years
16
Publishing since 2011
Seung-Oe Lim's research focuses on the molecular and cellular mechanisms underlying cancer progression and resistance to immune-based therapies, particularly in breast cancer. Key interests include how signaling proteins like EGFR and AKT1 drive tumor metabolism, invasion, and immune evasion, and how treatments such as PARP inhibitors and CD40-targeted antibodies can be engineered to boost anti-tumor immune responses. This work combines cell biology, cancer metabolism, and immunotherapy approaches, including antibody-based vaccine design.
Publication output was relatively steady and low (1-5 per year) from 2017-2022, followed by a sharp, likely data-driven spike in 2023 with a return to low output in subsequent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination
Journal of Controlled Release · 2026
- Abstract 6085: Engineered anti-CD40 agonist antibody as a novel cancer neoantigen vaccine carrier
Cancer Research · 2025
- Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
PubMed · 2023
- Abstract P3-07-24: Role of tumor cell-derived lactic acid in the PD-1/PD-L1 blockade resistant tumor
Cancer Research · 2023
- Data from EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
2023
- Data from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Data from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Data from EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
2023
- Supplemental Materials and Methods from EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
2023
- Supplemental Tables and Figures from EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
2023
- Supplemental Figure Legends from EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
2023
- Supplementary Tables and Figures from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Supplementary Figure Legends from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Supplementary Materials and Methods from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Supplementary Tables and Figures from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
2023
- Cancer Research×6
- Cancer Immunology Research×3
- PubMed×2
- Cells×2
- Molecular Cell×1
- Samantha Sharma
Biochemistry, Genetics and Molecular Biology · Indiana University
- Alyssa Min Jung Kim
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Wonkyung Oh
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Dennis J. Grencewicz
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Claire F. Verschraegen
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile